Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aimed at Hard-to-Treat GVHD enters early human testing

NCT ID NCT07138196

Recruiting now Disease control Sponsor: Qurient Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an oral drug called Q702 in 18 people with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of effectiveness. All participants have moderate or severe cGVHD after a stem cell transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Adrixetinib (Q702), an oral drug
What this could lead to
If it works, this could point toward a new treatment option for people with chronic GVHD that hasn't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, focused mainly on safety and dosing. It may not show clear benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC GRAFT VERSUS HOST DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, Spain

  • Hospital Clinic de Barcelona

    RECRUITING

    Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Marques de Valdecilla

    RECRUITING

    Santander, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    RECRUITING

    Majadahonda, Spain

  • Hospital Universitario Virgen de la Arrixaca

    RECRUITING

    Murcia, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, Spain

  • Instituto de Investigacion Sanitaria

    RECRUITING

    Valencia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.